Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 27, 2020

Novartis partners with life sciences companies to fight Covid-19

Novartis has partnered with a consortium of life sciences companies to rapidly develop, produce and deliver vaccines, diagnostics and treatments for Covid-19 coronavirus infection.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Novartis has partnered with a consortium of life sciences companies to rapidly develop, produce and deliver vaccines, diagnostics and treatments for Covid-19 coronavirus infection.

The partners will combine their assets, resources and expertise, working with the Bill & Melinda Gates Foundation, to accelerate the fight against the pandemic.

Novartis CEO Vas Narasimhan serves as a co-chair of a consortium of life science companies with headquarters in three continents.

Narasimhan said: “In addition to the individual contributions companies are already making, collective action is critical to ensure any promising studies into vaccines, drugs, and diagnostics are quickly scaled to people around the world who are affected by this pandemic.”

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

As well as Novartis, companies participating in the alliance involve Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline (GSK), Bristol-Myers Squibb, Merck (MSD), Pfizer, Eisai, Johnson & Johnson, Sanofi, Merck KGaA, BD and bioMérieux.

After a recent conference call with Gates Foundation, 15 companies agreed to share their molecular compound libraries with some existing safety and activity data.

The libraries will be shared alongside the Covid-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome and Mastercard earlier this month for screening for potential against the new viral infection.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU